AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT ID: NCT05602363
Last Updated: 2025-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
120 participants
INTERVENTIONAL
2023-08-01
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01868893
A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
NCT01035216
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
NCT00344786
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
NCT00301769
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
NCT07261163
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Dose escalation part will enroll up to 27 patients to evaluate safety profile and tolerance of docirbrutinib using 3+3 design. The starting dose of docirbrutinib in oral tablet form is 100 mg twice daily (200 mg/day). Dose escalation will continue up to the planned maximum dose level or until the maximum tolerated dose (MTD) has been identified.
Dose expansion part will enroll up to 48 CLL/SLL patients (Cohort 1), up to 35 NHL patients (Cohort 2), and up to 10 patients with prior pirtobrutinib treatment for an approved indication (Cohort 3). The first 30 patients in each Cohort 1 or 2 will be allocated to three dose levels (n=10 at each dose level) which will be selected based on the data from dose escalation. Preliminary efficacy and safety data from the first 30 patients in one of cohorts will be used to identify the provisional recommended Phase 2 dose (RP2D) level. Thereafter, up to a further 18 patients for Cohort 1 and up to a further 5 patients for Cohort 2 will be enrolled and allocated to the provisional RP2D level. Cohort 3 will be enrolled in parallel with Cohorts 1 and 2 and will be allocated to up to two dose levels (either n=10 at a single dose level or n=5 at each of 2 dose levels).
Study assessments will continue for 24 cycles (1 cycle = 28 days) or until disease progression, occurrence of unacceptable toxicity, or discontinuation because of other reasons. Patients will then be followed for survival status for a further 2 years.
RP2D will be determined based on all the data generated in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation
Dose escalation (3+3 design) and determination of MTD and DLTs
CLL/SLL or B-cell NHL patients will self-administer docirbrutinib oral tablet at multiple dose levels twice daily for 24 cycles (1 cycle = 28 days).
Docirbrutinib
oral tablet, twice daily
Dose Expansion
Cohort 1: CLL/SLL patients, Cohort 2: B-cell NHL patients, Cohort 3: CLL/SLL or B-cell NHL patients with prior treatment with pirtobrutinib (Jaypirca) for an approved indication
Patients will self-administer docirbrutinib oral tablet for 24 cycles (1 cycle = 28 days). Dose levels will be determined based on the result of dose escalation part.
Docirbrutinib
oral tablet, twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Docirbrutinib
oral tablet, twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provided written informed consent
* Histologically confirmed B-cell malignancy, including CLL/SLL, WM, MCL, MZL, or FL
* Patients with SLL, MCL, MZL, and FL: at least 1 radiographically measurable lesion
* Failed or are intolerant to ≥2 prior lines of systemic therapy
* ECOG Performance Status 0 to 2
* Adequate hematologic status (ie, absolute neutrophil count ≥0.75 × 10⁹/L, platelet count ≥50 × 10⁹/L, hemoglobin ≥8 g/dL) not requiring transfusion support or growth factors
* Adequate hepatic function
* Adequate renal function
* Ability to swallow tablets and comply with study requirements for the duration of study participation
* Male and female patients of reproductive potential: Willing to observe conventional and effective birth control methods
* Male patients: agree not to donate sperm during and for 6 months after the study
* Dose Expansion Cohort 3 patients: prior treatment with pirtobrutinib (Jaypirca) for an approved indication
Exclusion Criteria
* Investigational agent or anticancer therapy within 5 half-lives before the planned start of docirbrutinib, except therapeutic monoclonal antibody treatment which must be discontinued at least 4 weeks before the start of docirbrutinib
* Current treatment with investigational therapy or planned investigational therapy which would be concurrent with this study
* Requiring therapeutic anticoagulation with warfarin
* Current treatment with certain strong CYP3A4 inhibitors or inducers
* Treatment with proton pump inhibitors within 7 days before first dose of docirbrutinib
* Current treatment with strong P-glycoprotein inhibitors or strong BCRP inhibitors
* Refractory to transfusion support
* Major surgery within 4 weeks before planned start of docirbrutinib
* Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment
* Any unresolved toxicities from prior therapy greater than NCI CTCAE Version 5.0 Grade 2 at the time of starting study treatment except for alopecia
* History of allogeneic or autologous stem cell transplant or CAR-T therapy within the last 30 days
* Active second malignancy unless in remission with life expectancy \>2 years
* Known central nervous system (CNS) involvement by systemic lymphoma
* Active uncontrolled autoimmune cytopenia (eg, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura) where new therapy introduced or concomitant therapy escalated within the 4 weeks before study enrollment is required to maintain adequate blood counts
* Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months before planned start of docirbrutinib, or prolongation of the QT interval corrected for heart rate using Fridericia's Formula (QTcF) \>470 msec on at least 2 of 3 consecutive ECGs, and mean QTcF \>470 msec on all 3 ECGs, during Screening
* Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
* Positive for HIV. For patients with unknown HIV status, HIV testing will be performed at Screening
* Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of docirbrutinib
* Pregnant or lactating.
* Known hypersensitivity to any component or excipient of docirbrutinib
* Prior treatment with docirbrutinib
* Dose Escalation and Cohort 3 patients: prior treatment with noncovalent BTKi except pirtobrutinib (Jaypirca)
* Dose Expansion Cohort 1 and Cohort 2 patients: prior treatment with any noncovalent BTKi
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Carna Biosciences, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC Irvine Health
Orange, California, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
American Oncology Partners
Fort Wayne, Indiana, United States
University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, United States
Optum Medical Care PC
Westbury, New York, United States
Duke University
Durham, North Carolina, United States
Taylor Cancer Research Center
Maumee, Ohio, United States
Oncology Consultants
Houston, Texas, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
The Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Medical College of Wisconsin Cancer Center Clinical Trials Office
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C1763102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.